Suppr超能文献

急性缺血性卒中血管内治疗与静脉溶栓治疗的比较:21项随机试验的定量综述与荟萃分析

Endovascular Treatment Versus Intravenous Thrombolysis for Acute Ischemic Stroke: a Quantitative Review and Meta-Analysis of 21 Randomized Trials.

作者信息

Tan Chen-Chen, Wang Hui-Fu, Ji Jin-Long, Tan Meng-Shan, Tan Lan, Yu Jin-Tai

机构信息

Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.

Department of Neurology, Nanjing Medical University, Nanjing, China.

出版信息

Mol Neurobiol. 2017 Mar;54(2):1369-1378. doi: 10.1007/s12035-016-9738-0. Epub 2016 Feb 3.

Abstract

Emerging studies suggest that endovascular treatment (EVT) may be superior to intravenous thrombolysis for acute ischemic stroke (AIS). We performed a systematic review and meta-analysis of all randomized controlled trials (RCTs) to assess the efficacy and safety of endovascular treatment in patients with acute ischemic stroke as compared with intravenous thrombolysis. We assessed RCTs investigating EVT versus intravenous thrombolysis (IVT) published up to June 2015. In total, 21 studies of 4473 patients were included in the systematic review and meta-analysis. EVT significantly improved functional outcome at 90 days (risk ratio (RR) 1.35, 95 % confidence interval (CI) 1.18 to 1.55, I  = 61 %) and reduced the mortality (RR 0.81, 95 % CI 0.68 to 0.95, I  = 0 %), with similar symptomatic hemorrhagic transformation (SHT) rate (RR 1.12, 95 % CI 0.88 to 1.44, I  = 0 %). Based on the current data, endovascular therapy may produce good clinical outcomes with similar symptomatic hemorrhage and mortality as compared with intravenous thrombolysis in acute ischemic stroke. This advancing intervention is a landmark change in stroke treatment and could be of huge potential benefit to patients worldwide.

摘要

新兴研究表明,对于急性缺血性卒中(AIS),血管内治疗(EVT)可能优于静脉溶栓。我们对所有随机对照试验(RCT)进行了系统评价和荟萃分析,以评估与静脉溶栓相比,血管内治疗对急性缺血性卒中患者的疗效和安全性。我们评估了截至2015年6月发表的比较EVT与静脉溶栓(IVT)的RCT。在系统评价和荟萃分析中总共纳入了针对4473例患者的21项研究。血管内治疗在90天时显著改善了功能结局(风险比(RR)1.35,95%置信区间(CI)为1.18至1.55,I² = 61%)并降低了死亡率(RR 0.81,95%CI为0.68至0.95,I² = 0%),有相似的症状性出血转化(SHT)率(RR 1.12,95%CI为0.88至1.44,I² = 0%)。基于目前的数据,与急性缺血性卒中的静脉溶栓相比,血管内治疗可能产生良好的临床结局,且症状性出血和死亡率相似。这种不断发展的干预措施是卒中治疗的一个里程碑式变化,可能会给全球患者带来巨大的潜在益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验